Arxiv Universal PublishingsThe Role of SGLT2 Inhibitors in the Management of Heart FailureJobborov.O.OJobborov.O.OauthorMaksudova M.HMaksudova M.HauthorMurtozoyev E.AMurtozoyev E.AauthorSodium – glucose co-transporter 2 (SGLT2) inhibitors reduce blood glucose by inhibiting reabsorption of glucose from the proximal renal tubules. Initial studies showed that apart from reducing blood glucose they also reduce the combined endpoint of myocardial infarction, stroke, and cardiovascular death, hospitalization from heart failure, and occurrence of renal failure in patients with known cardiovascular disease or at high risk of developing cardiovascular disease. Recent studies have shown that these drugs also could be used in patients to treat heart failure or to slow the progression of renal failure, irrespective of whether the patients have diabetes or not. In this review, we discuss the clinical trial evidence for the use of SGLT2 inhibitors for the treatment of patients with heart failure with reduced ejection fraction and for the prevention of heart failure in patients with diabetes who are at high risk of cardiovascular events. The DAPA-HF study and the EMPERORREDUCED TRIAL have shown that Dapaglifozin and Empaglifozin could be used to treat patients with heart failure, with or without diabetes. SGLT2 inhibitors provide us with a new armamentarium for treatment of patients with a triad of diabetes, heart or renal disease. Their mechanism of action in prevention or treatment of patients with heart failure however still remains speculative.2024-01-28Maqola

For work being deposited by its own author: In self-archiving this collection of files and associated bibliographic metadata, I grant Arxiv Universal Publishings the right to store them and to make them permanently available publicly for free on-line. I declare that this material is my own intellectual property and I understand that Arxiv Universal Publishings does not assume any responsibility if there is any breach of copyright in distributing these files or metadata. (All authors are urged to prominently assert their copyright on the title page of their work.)

For work being deposited by someone other than its author: I hereby declare that the collection of files and associated bibliographic metadata that I am archiving at Arxiv Universal Publishings is in the public domain. If this is not the case, I accept full responsibility for any breach of copyright that distributing these files or metadata may entail.

Clicking on the Deposit Item Now button indicates your agreement to these terms.